Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31, 2025.

According to the announcement, revenue is projected to range from RMB1,368.81 million to RMB1,388.81 million, representing a year-on-year increase of approximately 39.61% to 41.65%. Net profit attributable to owners is expected to be between RMB162.43 million and RMB182.43 million, marking a year-on-year growth of around 384.26% to 443.88%. After deducting non-recurring items, net profit attributable to owners is anticipated to reach RMB104.92 million to RMB124.92 million, reflecting an increase of about 356.81% to 443.88% compared with the previous year.

The announcement notes that the expansion of overseas markets, alongside a recovery in the domestic biopharmaceutical industry, contributed to a rapid increase in revenue. A high-entry-barrier technological edge supported strong gross margins, and lean management initiatives improved overall operating efficiency, leading to significantly higher profitability.

All figures mentioned are based on preliminary calculations under the China Accounting Standards for Business Enterprises and have not been audited. Official results will be finalized in the 2025 annual report, and investors are advised to exercise caution in interpreting the preliminary data.